{"schema_version":"secwatch.filing_event.v1","accession":"0001576885-23-000047","form_type":"8-K","ticker":"ABOS","cik":"0001576885","company_name":"Acumen Pharmaceuticals, Inc.","filed_at":"2023-08-08T23:59:59+00:00","discovered_at":"2026-05-14T18:03:34.406430+00:00","generated_at":"2026-06-12T01:56:37.642200+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Acumen reports positive Phase 1 results for ACU193; Q2 net loss $11.6M, cash $172.2M + $122M offering","bullets":["Phase 1 INTERCEPT-AD trial met primary/secondary objectives; ACU193 showed 25% amyloid plaque reduction at 60 mg/kg (p=0.01).","ACU193 demonstrated near-maximal target engagement of toxic AβOs; low ARIA-E rate of 10.4%, symptomatic 2.1%; no drug-related SAEs.","Cash, equivalents & securities $172.2M at June 30; July follow-on offering added ~$122M net; runway into H2 2026.","Phase 2 study initiation expected H1 2024; FDA interaction anticipated Q4 2023 to inform development path.","Q2 2023 net loss $11.6M vs $10.2M YoY; R&D expenses $9.1M (up from $7.3M); no revenue."],"urls":{"canonical":"https://secwatch.observer/filing/0001576885-23-000047","json":"https://secwatch.observer/filing/0001576885-23-000047.json","markdown":"https://secwatch.observer/filing/0001576885-23-000047.md","text":"https://secwatch.observer/filing/0001576885-23-000047.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000047/0001576885-23-000047-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000047/abos-20230808.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-12T01:56:37.642200+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"ea60e00bbc2f8853743923626bcf4fd3ba110f03","claim":"Acumen Pharmaceuticals, Inc. reported the quarter ended June 30, 2023 results: net income Net loss was $11.6 million for the three-month period ended June 30, 2023.","evidence_excerpt":"Acumen Pharmaceuticals, Inc. (the “ Company ”) reported financial results and business highlights for the quarter ended June 30, 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1576885/000157688523000047/0001576885-23-000047-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Net income","value":"Net loss was $11.6 million for the three-month period ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}